Updates and Data 

Date last updated:10/19/2020

General comments: We provide these summary data in the spirit of transparency and open data sharing. Given the relatively small number of reported cases and preliminary nature of these reports, we do not recommend these data be used to inform clinical decisions at this time. Additionally, as many mild cases of COVID-19 do not undergo testing, these data may over-represent more severe cases in which COVID-19 testing was performed. 

Please use the following citation if referencing the data on this page: Balogh EA, Heron CE, Feldman SR, Huang WW. SECURE-Psoriasis Database Public Data Update. Www.covidpso.org. Accessed on MM/DD/YY.

Total number of cases reported: 19

 

 

 

Table 1: Patient demographics of initial reprots to SECURE-Psoriasis
Age and Gender Country and State or Territory of Residence  Race and Ethnicity Comorbidities Current Cigarette Smoking Current Alcohol Use Current Illicit Drug Use
Patient 1 39, F  USA, California White; Not Hispanic/Latino Crohn's Disease No No No
Patient 2 81, M USA, Washington  Middle Eastern; Not Hispanic/Latino Diabetes HTN No  Unknown No
Patient 3 81, M USA, New York  White; Not Hispanic/Latino  CVD No No No
Patient 4 38, M USA, Oklahoma  White; Not Hispanic/Latino HTN No Unknown No
Patient 5 89, M USA, Michigan  White; Not Hispanic/Latino CVD 
Diabetes
HTN
Cancer 
History of Stroke		 No No No
Patient 6 65, M USA, Puerto Rico  White; Not Hispanic/Latino Unknown No No No
Patient 7 74, F USA, Indiana  White; Not Hispanic/Latino CVD 
Diabetes
COPD
HTN
CKD
Other (nursing home)		 No No No
Patient 8  69, M  Italy  White; Not Hispanic/Latino Diabetes
HTN
History of Stroke
 No No No
Patient 9  64, M USA, New York White; Unknown CVD
Diabetes
Obesity		 No Unknown No
Patient 10 47, M USA, Michigan Unknown; Hispanic/Latino Diabetes
Hyperlipidemia		 No Yes No
Patient 11 67, M USA, Michigan White; Not Hispanic/Latino Diabetes
HTN
Hyperlipidemia		 No Yes No
Patient 12 29, F Italy White; Not Hispanic/Latino None  No No No
Patient 13 71, M Ecuador Other; Hispanic/Latino Diabetes
HTN		 No No No
Patient 14 54, M USA; Louisana White; Not Hispanic/Latino None No No No
Patient 15 54, M Italy White; Not Hispanic/Latino Depression
HTN		 No No No
Patient 16  20, F USA; Massachusetts Asian; Unknown None  Yes Yes Unknown
Patient 17 47, M Canada White; Unknown Crohn's Disease No Yes No
Patient 18 47, F USA; Wisconsin White; Not Hispanic/Latino Asthma No Yes No
Patient 19 59, F USA; Massachusetts Unknown; Unknown Diabetes
Depression
HTN		 Unknown Unknown Unknown
 CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CVD: Cardiovascular disease; F: Female; HTN: Hypertension; M: Male; USA: United States of America;

 

Table 2: Patient psoriasis diagnosis, severity, and therapy
Psoriasis diagnosis Psoriasis Severity at Time of COVID-19 Infection (Physician Global Assessment of average lesion character)
 Estimated Body Surface Area Affected (%)
 Psoriasis Medications
 Medication Dose and Dosing Interval  Medication Stopped due to COVID-19 
Patient 1 Intertriginous Clear 0%
  • Stelara (ustekinumab)
  • Unknown; unknown
 No
Patient 2 Plaque Moderate 2%
  • Stelara (ustekinumab)
  • Phototherapy

90 mg; Q10 weeks

311 laser weekly

 No
Patient 3 Scalp Mild 2% Siliq (brodalumab) 120 mg; Q2 weeks No
Patient 4 Plaque Mild 4% Taltz (ixekizumab)
Lexette
Sorilux		 80 mg; Q4 weeks
unknown; as needed
unknown as needed		 No
Patient 5 Plaque Unknown Unknown Trimcinolone cream 0.025%; as needed No
Patient 6 Plaque Almost clear 1% Taltz (ixekizumab) 80 mg; unknown Yes
Patient 7  Plaque Moderate 5-8% Tremfya (guselkumab) 100 mg; unknown Yes
Patient 8  Plaque  Mild 7% Secukinumab 300 mg; Q4 weeks Yes
Patient 9 Plaque Almost clear 1% Ustekinumab 90 mg; Q10 weeks No
Patient 10 Plaque Clear 0% Guselkumab 100 mg; Q8 weeks No
Patient 11 Plaque  Almost clear <1% Adalimumab 40 mg; Q2 weeks  No
Patient 12 Plaque Clear 0% Fumaric acid esters 360 mg; daily No
Patient 13 Plaque Clear  0% Secukinumab 300 mg; Q4 weeks No
Patient 14 Plaque Almost clear 1%  Apremilast 30 mg; daily No
Patient 15 Plaque Clear 0% Secukinumab 300 mg; Q4 weeks Yes
Patient 16  Plaque Clear 0% Guselkumab 100 mg; Q8 weeks No
Patient 17 Plaque Mild 3% Clobetasol propionate ointment As needed No
Patient 18 Plaque Mild 2% Secukinumab 300 mg; Q3 weeks Yes
Patient 19 Plaque Clear 0% Broalumab 210 mg; Q2 weeks Yes
Mg - milligrams; Q2 weeks - every two weeks; Q4 weeks - Every four weeks; Q10 weeks; every ten weeks 

 

 

Table 3: Summary of COVID-19 disease course in reported patients




COVID-19 year of diagnosis and days of illness  New Psoriasis Symptoms at Time of Diagnosis and Changes, if Applicable Severity of COVID-19 (hospitalization; death) Length of Hospitalization if Applicable Intensive Care Unit and Ventilator Requirement if Applicable Medications and/or Investigational Therapites Used to Treat COVID-19? 
Patient 1  2020; 5 days Yes; small psoriatic papules and plaques (guttate pattern) No; No N/A N/A Unknown
Patient 2 2020; 14 days No No; No N/A N/A No
Patient 3  2020; 2 days  No Yes; No 3 days No; No No
Patient 4 2020; 2 dyas No No; No N/A N/A  No
Patient 5 2020; Unknown Unknown Unknown; Yes Unknown Unknown No
Patient 6 2020; Unknown Unknown Yes; No Unknown Yes; Yes Tocilizumab
Patient 7 2020; Unknown Unknown No; No N/A N/A Unknown
Patient 8  2020; 30 days No No; No N/A N/A Hydroxchloruine
Patient 9 2020; 0 days No No; No N/A N/A  No
Patient 10 2020; 14 days No No; No N/A N/A No
Patient 11 2020; 13 days No No; No N/A N/A No
Patient 12 2020; 14 days  No No; No N/A N/A No
Patient 13 2020; 24 days No No; No N/A N/A Azithromycin
Patient 14 2020; 0 days No No; No N/A N/A No
Patient 15 2020; 40 days No No; No N/A N/A Hydroxchloroquine
Patient 16  2020; Unknown  No Unknown; No N/A N/A None
Patient 17 2020; 40 Yes; Pruritus, cutaneous plaques, guttate pattern, palmoplantar psoriasis, arthritis No; No N/A N/A None
Patient 18 2020; 14 No No; No N/A N/A Unknown
Patient 19 2020; Unknown Unknown No; Unknown Unknown Unknown Unknown

 

 

Table 4:Cases reported by state or territory (US only)
US State or Country N
California 1
Indiana 1
Massachusetts  2
Michigan 3
New York 2
Oklahoma 1
Puerto Rico 1
Washington 1
Louisana  1
Wisconsin 1
Canada  1
Italy 3
Ecuador 1

 

Table 5: Reported cases and COVID-19 outcomes classified by psoriasis therapy
  Total (N) Outpatient only (n, %) Hospitalized (n, %) ICU (n, %) Ventilator
(n, %)
 
 Death (n, %) ICU/Ventilator/Death (n, %) 
Ustekinumab 3 3, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Phototherapy 1 1, 100% 0,0%  0,0% 0,0% 0,0% 0,0%
Brodalumab 2 1, 100% 1, 50% 0,0% 0,0% 0,0% 0,0%
Ixekizumab  2 1, 50% 1, 50% 1, 50% 1, 50% 0,0% 0,0%
Halobetasol propionate  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Clobetasol propionate  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Calcipotriene  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Triamcinolone  1 uknown unknown unknown unknown 1, 100% unknown
Guselkumab  3 2, 66% 0,0% 0,0% 0,0% 0,0% 0,0%
Secukinumab  4 4, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Etanercept  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Fumaric Acid Esters  1 1, 100% 0,0% 0,0% 0,0%  0,0% 0,0%
Apremilast  1  1, 100% 0,0% 0,0% 0,0% 0,0% 0,0% 

 

Table 6: Reported cases and COVID-19 outcomes classified by psoriasis medication class
Total (N) Outpatient only (n,%) Hospitalized (n,%) ICU (n,%)  Ventilator (n,%) Death (n,%) ICU/Ventilator/Death (n,%)
IL-17i 8 5, 62% 2, 25% 1, 13% 1, 13% 0, 0% 0, 0%
IL-23i 5 5, 100% 0, 0% 0,0% 0,0% 0,0% 0,0%
TNFi 1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Phototherapy  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Topical corticosteroids  3 unknown unknown unknown unknown 1, 33% unknown
Vitamin D derivatives  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%
Fumaric acid esters  1 1, 100% 0,0%  0,0% 0,0% 0,0% 0,0%
PDE4i  1 1, 100% 0,0% 0,0% 0,0% 0,0% 0,0%